Back to Authors

Ma, Daniel

Mayo Clinic

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, U.S.A.

Citations 6

Human Papillomavirus–Associated Anogenital Pathology in Females With HPV‐Positive Oropharyngeal Squamous Cell Carcinoma
Larish, Alyssa , Moore, Eric J. , Routman, David M. , Janus, Jeffrey R. , Price, Katharine A. , Neben-Wittich, M.A. , Foote, Robert L. , Abel, Kathryn M. Van , Yin, Linda, Glaser, Gretchen , Moore, Eric, Bakkum-Gamez, Jamie, Routman, David, Ma, Daniel, Price, Daniel, Janus, Jeffrey, Price, Katharine, Chintakuntlawar, Ashish, Neben-Wittich, Michelle, Foote, Robert, Van Abel, Kathryn, Van Abel, Kathryn M , Routman, David M , Yin, Linda X. , Bakkum‐Gamez, Jamie N. , Daniel, J. , Price, Daniel L. , Chintakuntlawar, Ashish V.

Otolaryngology–Head and Neck Surgery | July 14, 2020 | Volume: 164 | Issue: 2 | Pages: 369-374

10.1177/0194599820941499 Get It

We sought to determine the incidence and location of human papillomavirus (HPV)–associated anogenital disease in women with HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC) via a retrospective cohort study with prospective contact to update history at Mayo Clinic in Rochester, Minnesota. Females undergoing treatment for nonmetastatic HPV‐positive OPSCC from 2011 to 2019 were identified. Clinical history and outcomes were abstracted from medical records. Patients without documented anogenital history were contacted, consented, and administered a survey, and external records were requested and reviewed. Seventeen of 46 patients (37.0%) had a history of anogenital HPV‐associated disease, and 16 of 17 (94.1%) required procedures to diagnose or treat HPV lesions. The cervix was the most common site (16/17, 94.1%). Procedures included colposcopy (n = 6), cervical excision (n = 3), cryotherapy (n = 4), and hysterectomy (n = 3). One case of fatal cervical carcinoma was noted, diagnosed 1 year following OPSCC. Three of 17 (17.6%) had HPV‐related vulvovaginal disease, and 1 of 17 had anal disease. Patients with a history of HPV‐positive OPSCC may be at elevated risk for HPV‐associated anogenital disease.
Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience
Gamez, Mauricio E. , Jeans, Elizabeth B. , Hinni, Michael L., Moore, Eric J. , Young, Geoffrey D., McGee, L.A. , Buras, Matthew , Patel, Samir H. , Moore, Eric, Young, Geoffrey, Ma, Daniel, McGee, Lisa, Daniel, J. , Buras, Matthew R

The Laryngoscope | July 6, 2017 | Volume: 128 | Issue: 2 | Pages: 373-377

10.1002/lary.26725 Get It

Objectives/HypothesisSarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes.Study DesignRetrospective study. Median follow‐up 45 months.MethodsThere were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression‐free survival (PFS), and local control (LC) were conducted using the Kaplan‐Meier method.ResultsThe majority of patients were elderly males (92%) with a smoking history (74%) presenting with early‐stage disease (71%). Surgery alone was the primary treatment in 27 patients (71%). Nine patients (25%) were treated with adjuvant radiation due to initial stage or high‐risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3–75.0 Gy). A total of 15 patients (39%) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five‐year OS, PFS, and LC were 63%, 46%, and 72%, respectively. Subgroup analysis by stage I versus higher stages (II–IV) showed an OS of 80% versus 43% (P = .030), PFS of 65% versus 18% (P = .003), and LC of 84% versus 57% (P = .039).ConclusionsSarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early‐stage tumors are treated appropriately with single‐modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.Level of Evidence4. Laryngoscope, 128:373–377, 2018
Outcomes and patterns of failure for sinonasal undifferentiated carcinoma (SNUC): The Mayo Clinic Experience
Gamez, Mauricio E. , Halyard, Michele Y. , Wong, William W. , Vargas, Carlos , Foote, Robert L. , Patel, Samir H. , Ma, Daniel, Ko, Stephen J. , Lal, Devyani , Daniel, J.

Head & Neck | May 31, 2017 | Volume: 39 | Issue: 9 | Pages: 1819-1824

10.1002/hed.24834 Get It

Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer
Gamez, Mauricio E. , Halyard, Michele Y. , Hinni, Michael L., Hayden, Richard E. , Nagel, Thomas H. , Vargas, Carlos , Wong, William W. , Curtis, Kelly K., Zarka, Matthew A., Patel, Samir H. , Ma, Daniel, Daniel, J.

Annals of Otology, Rhinology & Laryngology | January 7, 2017 | Volume: 126 | Issue: 3 | Pages: 185-191

10.1177/0003489416681580 Get It

Purpose: To report the outcomes of patients with favorable risk oropharyngeal cancer that underwent adjuvant radiation therapy with omission of the primary site from the clinical target volume (CTV). Material/Methods: A retrospective study of 40 patients treated with transoral surgery (TOS) followed by neck only radiation using intensity modulated radiation therapy (IMRT) with exclusion of the primary site. For all patients, a CTV of the primary surgical bed was contoured to obtain the estimated incidental dose to the primary site. Results: Median follow-up was 51 months (range, 13-155 months). The median radiation therapy (RT) dose to the neck was 6000 cGy (range, 5400-6400 cGy). The mean incidental dose to the primary tonsillar site was 4320 cGy (SD ± 480 cGy) and to the primary base of tongue site was 4060 cGy (SD ± 420 cGy). There were no local failures and only 1 regional failure, resulting in 97.5% locoregional control rate at 4 years. Two patients developed distant metastases, without evidence of locoregional recurrence, for a 4-year overall survival rate of 97%. Conclusions: Our analysis suggests that mucosal sparing RT after TOS in favorable risk oropharyngeal cancer patients may provide comparable oncologic and improved functional outcomes compared to conventional treatment in selected patients.
Oncologic outcomes of selective neck dissection in HPV‐related oropharyngeal squamous cell carcinoma
Zenga, Joseph , Jackson, Ryan S. , Graboyes, Evan M. , Sinha, Parul , Lindberg, Miranda, Martin, Eliot J., Rich, Jason T. , Moore, Eric J. , Haughey, Bruce H. , Ma, Daniel, Daniel, J. , Thorstad, Wade

The Laryngoscope | September 16, 2016 | Volume: 127 | Issue: 3 | Pages: 623-630

10.1002/lary.26272 Get It

ObjectivesTo examine outcomes of selective neck dissection (SND) in patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC) who present with clinical neck disease.Study DesignMulti‐institutional retrospective review.MethodsTwo institutional databases of patients with HPV‐related OPSCC were reviewed to identify patients with clinical (c) N1‐N3 neck disease who underwent SND ± adjuvant therapy.ResultsThree hundred and twenty‐four patients were identified with a median follow‐up of 49 months (range 3–199 months). All patients underwent transoral resection of the primary tumor and SND, including levels II–IV and ± levels I or V, with resection of additional nonlymphatic tissue (extended SND) as indicated by extent of disease, including the spinal accessory nerve (7%), the internal jugular vein (13%), and the sternocleidomastoid muscle (8%). Two hundred and seventy (83%) patients underwent adjuvant radiation. There were 13 (4%) regional recurrences and 19 (6%) distant recurrences. Regional control following salvage was 98%. On univariable analysis, absence of radiation was associated with regional recurrence (odds ratio [OR] 9.2, 95% confidence interval [CI] 2.9–29.4). On multivariable analysis, adjuvant radiation was associated with improved disease‐free survival (DFS) (OR 0.27, 95% CI 0.14–0.53) but lost significance for overall (OS) and disease‐specific survival (DSS) (P > 0.05). Five‐year Kaplan‐Meier estimates for OS, DSS, and DFS were 88% (95% CI 84%–92%), 93% (95% CI 89%–96%), and 83% (95% CI 78%–87%), respectively.ConclusionIn HPV‐related OPSCC presenting with clinical neck disease, a SND ± additional tissue resection and adjuvant therapy, when indicated, provides excellent long‐term regional control. Omission of radiotherapy increases the risk of regional recurrence, although it may not significantly impact OS or DSS. It appears unnecessary to routinely perform a comprehensive neck dissection.Level of Evidence4. Laryngoscope, 127:623–630, 2017